Meeting schedule & fees

Meeting schedule & fees

The MREC NedMec does not have a deadline for mail submission, except for new research files and response letters concerning ‘important changes’ as these need to be discussed by the whole MREC chamber (see further below). Mail is processed in the order in which it was received and put on the agenda as soon as possible, depending on how busy the MREC’s schedule is. For new files submitted, you will receive notification of the date of first discussion.

Meeting schedule & timelines uitklapper, klik om te openen

The MREC consists of three chambers which each have two meetings per month:

  • Chamber O (Wednesdays in even weeks)
  • Chamber A (Tuesdays in even weeks)
  • Chamber G (Tuesdays in odd weeks)

Chamber O reviews oncology research, Chamber G reviews other drug researches (and if necessary also researches with Medical Devices), and Chamber A reviews the other researches (and if necessary also drug researches). All three chambers review research with adults as well as research with minors. 

Once a research file has been assigned to a chamber, this chamber will also review the response to questions, etc.

Deadlines for submissions and chamber agendas

New files and responses to ‘important changes’ must be in the possession of the MREC at the latest of two weeks before the meeting, on Tuesday or Wednesday at 12:00, due to the processing by the secretariat and the preparation of the meeting.

Files to be discussed will be put on the agendas of the chambers in the order in which they were received. Before a research file is put on the agenda, it is checked for completeness. Incomplete files will not be discussed. The investigator will be informed via e-mail if a file is incomplete.


The MREC’s general chairman and the chairpersons of the three chambers together make up the MREC’s Executive Committee; they meet up every Wednesday

The Executive Committee is authorised on behalf of the MREC to take decisions which have been delegated to the Executive Committee. If a chamber has decided that a few minor changes are required in a protocol, the study will be reviewed during a meeting of the Executive Committee (possibly after consultation with a number of committee members). The review by the Executive Board will take place on Tuesday. This also applies to amendments, SAEs, SUSARs and other correspondence, unless consideration in a meeting of the Chamber is necessary.


Meeting schedule and deadlines for 2022
Meeting schedule and deadlines for 2023

When will I hear about the result? uitklapper, klik om te openen

It is only after the first submission of a new research file that the applicant will receive confirmation of receipt, including information on:

  • the chamber to which the research has been assigned
  • the date of first discussion
  • any fees associated with the review

Within 14 days after the meeting, you will receive the MREC’s decision or a request for changes/additions to the research file. This period also applies to documents discussed by the Executive Committee.

The term within which the MREC must decide on your application will be stated in the ToetsingOnline portal. Via ToetsingOnline you can also keep track of the remaining decision period.

Fees for review uitklapper, klik om te openen

Rates 2022

The fees for the review of research will change per 01-01-2022. New studies or amendments received before 31-12-2021 will receive an invoice with the 2021 review fees (even though the review took place in 2022). 

In the download below the fees for 2022 can be found for research directly submitted to the MREC. For information on the rates for the reviewing of clinical research with a medicinal product (CTR) and research with a medical device (article 62/74.2 MDR), from 31 January 2022, please visit the website of the CCMO. Website CCMO - rates

N.B. As of the 1th of July 2022, a rate will be charged for assessment of an IMPD in drug research protocols that are still submitted to the MREC under the CTD or an IMDD in MDR research. These rates will be in accordance with the rates of the CTR/MDR (art. 62/74.2).


Fees for review (valid as of 01-01-2022)

Participating institutions: UMC Utrecht, Prinses Máxima Centrum for pediatric oncology and Antoni van Leeuwenhoek

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

NedMec maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid